Hemophilia B is caused by mutations in the F9 gene, which provides instructions for making a blood clotting protein called factor IX. When this gene is altered, the body produces too little factor IX or a version that doesn’t work properly, leading to prolonged bleeding. The condition affects roughly 1 in 20,000 male births worldwide.
The F9 Gene and Factor IX
The F9 gene sits on the X chromosome and contains the blueprint for factor IX, a protein essential to blood clotting. More than 900 different mutations in this gene have been identified. The most common type involves a change to a single DNA building block, which is enough to disrupt the protein’s function. A smaller percentage of mutations involve larger-scale changes, such as deletions, insertions, or rearrangements of DNA segments within the gene.
Factor IX normally circulates in the blood in an inactive form. When you’re injured, a chain reaction of clotting proteins activates it. On its own, activated factor IX is a weak enzyme. It reaches full strength only when it pairs with another clotting protein (factor VIII) on cell membranes, where together they accelerate the next step of clotting by roughly a millionfold compared to factor IX acting alone. This partnership is critical: without enough functional factor IX, the clotting chain stalls and bleeding continues far longer than it should.
How Hemophilia B Is Inherited
Because the F9 gene is located on the X chromosome, hemophilia B follows an X-linked inheritance pattern. Males have one X and one Y chromosome, so a single mutated copy of the F9 gene is enough to cause the disorder. There’s no backup copy on the Y chromosome. Females have two X chromosomes, so a normal copy on one X can often compensate for a mutated copy on the other. This is why hemophilia B overwhelmingly affects males.
A woman who carries one mutated F9 gene is called a carrier. If she has a son, there’s a 50% chance he will inherit the mutated gene and have hemophilia B. Each daughter has a 50% chance of becoming a carrier herself. Carriers sometimes experience mild bleeding symptoms, and in rare cases, their symptoms can be as serious as those in males with the disorder. This can happen when one X chromosome is disproportionately silenced, when both X chromosomes carry a mutation, or when one X chromosome is missing or nonfunctional.
A father with hemophilia B will pass his mutated X chromosome to all of his daughters (making them carriers) but to none of his sons, since sons receive his Y chromosome instead.
Cases Without Family History
About 30% of hemophilia B cases are sporadic, meaning the affected person is the first in their family with the condition. These cases arise from new (de novo) mutations in the F9 gene that occur spontaneously, either in the egg, the sperm, or during early embryonic development. This means a child can be born with hemophilia B even when neither parent has a family history of bleeding disorders. The mutation can then be passed to future generations following the standard X-linked pattern.
Severity Depends on Factor IX Levels
Not all F9 mutations have the same impact. The type and location of the mutation determine how much functional factor IX the body can still produce, which directly dictates how severe the condition is. Hemophilia B is classified into three levels based on the percentage of normal factor IX activity in the blood:
- Severe: Less than 1% of normal factor IX activity. Bleeding episodes can occur spontaneously, often into joints and muscles, without any obvious injury.
- Moderate: 1% to 5% of normal activity. Bleeding typically follows minor injuries or minor surgical procedures, though occasional spontaneous bleeding can occur.
- Mild: 6% to 40% of normal activity. Bleeding problems usually surface only after significant trauma, surgery, or dental work, and can go undiagnosed for years.
Hemophilia B Leyden
A handful of mutations near the beginning of the F9 gene cause an unusual variant called hemophilia B Leyden. People with this form have low factor IX levels throughout childhood, but after puberty, their levels gradually rise at a rate of about 5% per year. The mutations affect a regulatory region (the gene’s promoter) that responds to hormonal changes during adolescence. In some cases, factor IX levels eventually reach a range where bleeding symptoms improve significantly or even resolve. This makes hemophilia B Leyden distinct from all other forms of the condition, where severity remains constant throughout life.
Acquired Factor IX Deficiency
In rare cases, a person who wasn’t born with hemophilia B can develop factor IX deficiency later in life. This happens when the immune system mistakenly produces antibodies that attack factor IX. Acquired hemophilia is far more commonly directed against factor VIII (causing acquired hemophilia A), but it can target factor IX as well. About half of acquired hemophilia cases are linked to an identifiable trigger, including autoimmune diseases, certain cancers, pregnancy, and some medications. In the other half, no clear cause is found. Acquired hemophilia typically appears in older adults with no prior bleeding history and requires a different treatment approach than the inherited form.